If you have been reading about aminoisobutyric acid and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
=== Opposition to COVID-19 vaccine requirements (2021) === In October 2021, the In-N-Out location in San Francisco was ordered closed by the San Francisco Department of Public Health (SFDPH), for failure to enforce the public health order requiring that all dine-in patrons of restaurants present proof that they are fully vaccinated for COVID-19. The location had posted signage warning of the mandate, but the SFDPH received complaints that it was not actually enforced. The company's chief legal officer Arnie Wensinger stated that the company "fiercely disagree[s] with any government dictate that forces a private company to discriminate against customers who choose to patronize their business". The location was allowed to re-open for takeout service only until it demonstrates "an adequate process and procedure for complying with the health order". Later that month, after an In-N-Out location in Contra Costa County was similarly ordered closed by public health for not complying with its vaccine mandate, all In-N-Out locations in the region closed their dining rooms and began operating with takeout service only. The locations attracted anti-mandate demonstrations in support of the company.
The constitution grants freedom of religion, while establishing Islam as the "religion of the Federation". The freedom to change or leave a religion is limited for Muslims. According to the Population and Housing Census 2020 figures, ethnicity and religious beliefs correlate highly. Approximately 63.5% of the population practise Islam, 18.7% practise Buddhism, 9.1% Christianity, 6.1% Hinduism and 1.3% practise Confucianism, Taoism and other traditional Chinese religions. 2.7% declared no religion or practised other religions or did not provide any information. The states of Sarawak and Penang, as well as the federal territory of Kuala Lumpur have non-Muslim majorities. Sunni Islam of the Shafi'i school of jurisprudence is the dominant branch of Islam in Malaysia, while 18% are nondenominational Muslims. The Malaysian constitution strictly defines what makes a "Malay", defining Malays as those who are Muslim, speak Malay regularly, practise Malay customs, and lived in or have ancestors from Brunei, Malaysia and Singapore. Statistics from the 2010 Census indicate that 83.6% of the Chinese population identify as Buddhist, with significant numbers of adherents following Taoism (3.4%) and Christianity (11.1%), along with small Muslim populations in areas like Penang. The majority of the Indian population follows Hinduism (86.2%), with a significant minority identifying as Christians (6.0%) or Muslims (4.1%). Christianity is the predominant religion of the non-Malay bumiputera community (46.5%), while 40.4% identify as Muslims.
== Receptor == The receptor for CNMa (CG33696) is a G protein-coupled receptor. Phylogenetic analysis identified two separate clades of CNMaRs in arthropod species, but many taxa retain only one. Existence of two paralogous CNMaRs suggests that CNMaR has additional ligands in some insect species. This assumption is also supported by absence of the gene for CNMa in the genome of Lepidopteran species (such as Bombyx mori and Danaus plexippus) that retain the CNMaR.
Platelet basic protein (PBP) is a protein that in humans is encoded by the gene PPBP (previously CXCL7). PBP is a precursor protein that is cleaved into multiple distinct active proteins, notable Connective tissue-activating peptide III (CTAP-III), Beta-thromboglobulin (Beta-TG), Neutrophil-activating peptide 2 (NAP-2), TC-1, and TC-2. PPBP is first translated into the precursor molecule pro-platelet basic protein (PPBP), the first 34 amino acids of which correspond to the signal peptide, while the remaining amino acid residues at positions 35-128 compose PBP. PBP is a protein that is released in large amounts from platelets following their activation. It stimulates various processes including mitogenesis, synthesis of extracellular matrix, glucose metabolism and synthesis of plasminogen activator.
Sources: en.wikipedia.org
=== 2013 class action lawsuit === In 2013, a proposed class action lawsuit, Jennifer L Saavedra v. Eli Lilly and Company, was brought against Eli Lilly claiming that the Cymbalta label omitted important information about "brain zaps" and other symptoms upon cessation. Eli Lilly moved for dismissal per the "learned intermediary doctrine" as the doctors prescribing the drug were warned of the potential problems and are an intermediary medical judgment between Lilly and patients; in December 2013, Lilly's motion to dismiss was denied. In December 2014, class certification was denied. A second attempt at certification in 2015 also failed.
Butyl acrylate is of low acute toxicity with an LD50 (rat) of 3143 mg/kg. In rodent models, butyl acrylate is metabolized by carboxylesterase or reactions with glutathione; this detoxification produces acrylic acid, butanol, and mercapturic acid waste, which are excreted. Exposure can occur through inhalation, skin and/or eye contact absorption, and ingestion. Symptoms may be dependent on exposure route, with skin and eye contact manifesting in redness, pain, and sensitivity; inhalation resulting in burning sensations, cough, shortness of breath, and sore throat; and ingestion resulting in abdominal pain, nausea, vomiting, and diarrhoea.
To reduce pain the use of an exercise program of 13 to 24 weeks is recommended, with each session lasting 30 to 60 minutes. When different exercise programs are compared, aerobic exercise is capable of modulating the autonomic nervous function of fibromyalgia patients, whereas resistance exercise does not show such effects. A 2022 meta-analysis found that aerobic training showed a high effect size while strength interventions showed moderate effects. Meditative exercise seems preferable for improving sleep, with no differences between resistance, flexibility, and aquatic exercise in their favorable effects on fatigue.
Sources: en.wikipedia.org
==== 1.B. β-Barrel porins and other outer membrane proteins ==== 1.B.1 General bacterial porin family 1.B.2 Chlamydial porin (CP) family 1.B.3 Sugar porin (SP) family 1.B.4 Brucella-Rhizobium porin (BRP) family 1.B.5 Pseudomonas OprP porin (POP) family 1.B.6 OmpA-OmpF porin (OOP) family 1.B.7 Rhodobacter PorCa porin (RPP) family 1.B.8 Mitochondrial and plastid porin (MPP) family 1.B.9 FadL outer membrane protein (FadL) family 1.B.10 Nucleoside-specific channel-forming outer membrane porin (Tsx) family 1.B.11 Outer membrane fimbrial usher porin (FUP) family 1.B.12 Autotransporter-1 (AT-1) family 1.B.13 Alginate export porin (AEP) family 1.B.14 Outer membrane receptor (OMR) family 1.B.15 Raffinose porin (RafY) family 1.B.16 Short chain amide and urea porin (SAP) family 1.B.17 Outer membrane factor (OMF) family 1.B.18 Outer membrane auxiliary (OMA) protein family 1.B.19 Glucose-selective OprB porin (OprB) family 1.B.20 Two-partner secretion (TPS) family 1.B.21 OmpG porin (OmpG) family 1.B.22 Outer bacterial membrane secretin (secretin) family 1.B.23 Cyanobacterial porin (CBP) family 1.B.24 Mycobacterial porin 1.B.25 Outer membrane porin (Opr) family 1.B.26 Cyclodextrin porin (CDP) family 1.B.31 Campylobacter jejuni major outer membrane porin (MomP) family 1.B.32 Fusobacterial outer membrane porin (FomP) family 1.B.33 Outer membrane protein insertion porin (Bam complex) (OmpIP) family 1.B.34 Corynebacterial porins 1.B.35 Oligogalacturonate-specific porin (KdgM) family 1.B.39 Bacterial porin, OmpW (OmpW) family 1.B.42 Outer membrane lipopolysaccharide export porin (LPS-EP) family 1.B.43 Coxiella porin P1 (CPP1) family 1.B.44 Probable protein translocating porphyromonas gingivalis porin (PorT) family 1.B.49 Anaplasma P44 (A-P44) porin family 1.B.48 Curli-like transporters 1.B.54 Intimin/Invasin (Int/Inv) or Autotransporter-3 family 1.B.55 Poly-acetyl-D-glucosamine porin (PgaA) family 1.B.57 Legionella major-outer membrane protein (LM-OMP) family 1.B.60 Omp50 porin (Omp50 Porin) family 1.B.61 Delta-proteobacterial porin (Delta-porin) family 1.B.62 Putative bacterial porin (PBP) family 1.B.66 Putative beta-barrel porin-2 (BBP2) family 1.B.67 Putative beta barrel porin-4 (BBP4) family 1.B.68 Putative beta barrel porin-5 (BBP5) superfamily 1.B.70 Outer membrane channel (OMC) family 1.B.71 Proteobacterial/verrucomicrobial porin (PVP) family 1.B.72 Protochlamydial outer membrane porin (PomS/T) family 1.B.73 Capsule biogenesis/assembly (CBA) family 1.B.78 DUF3374 electron transport-associated porin (ETPorin) family
On 23 July 1952, a law combined the GDR's municipal districts (Kreise) into 14 regional districts (Bezirke), and subsequently, on 25 July 1952, the state governments transferred their administrative tasks to the new regional districts. With this law, the Länder were in effect dissolved, and the GDR had become a highly centralized state. While they formally remained in existence, they no longer had any political or administrative functions. The Bezirke were drawn without regard to the borders of the Länder and each named after their capitals, from north to south: Rostock, Neubrandenburg, Schwerin, Potsdam, Frankfurt (Oder), Magdeburg, Cottbus, Halle, Leipzig, Erfurt, Dresden, Karl-Marx-Stadt (named Chemnitz until 1953), Gera and Suhl. The Länderkammer also remained in existence and its members were elected in 1954 by combined sessions of the Bezirkstage (district assemblies) in each Land and in 1958 directly by the Bezirkstage. However, on 8 December 1958, the Länderkammer formally dissolved itself with no objections being raised. The Länder continued to exist de jure up until the entry into force of the 1968 Constitution, which formalized their abolition. Due to its special status, East Berlin was originally not counted as a Bezirk. In 1961, after the construction of the Berlin Wall, East Berlin came to be recognised in GDR administration as a 15th district, though it retained a special status until the adoption of the 1968 Constitution formally designated it as Bezirk Berlin.
The most common mechanism of stimulation of acupuncture points employs penetration of the skin by thin metal needles, which are manipulated manually or the needle may be further stimulated by electrical stimulation (electroacupuncture). Acupuncture needles are typically made of stainless steel, making them flexible and preventing them from rusting or breaking. Needles are usually disposed of after each use to prevent contamination. Reusable needles when used should be sterilized between applications. In many areas, only sterile, single-use acupuncture needles are allowed, including the State of California. Needles vary in length between 13 and 130 millimetres (0.51 and 5.12 in), with shorter needles used near the face and eyes, and longer needles in areas with thicker tissues; needle diameters vary from 0.16 mm (0.006 in) to 0.46 mm (0.018 in), with thicker needles used on more robust patients. Thinner needles may be flexible and require tubes for insertion. The tip of the needle should not be made too sharp to prevent breakage, although blunt needles cause more pain. Apart from the usual filiform needle, other needle types include three-edged needles and the Nine Ancient Needles. Japanese acupuncturists use extremely thin needles that are used superficially, sometimes without penetrating the skin, and surrounded by a guide tube (a 17th-century invention adopted in China and the West). Korean acupuncture uses copper needles and has a greater focus on the hand.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.